Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): Week 28 results from the ongoing phase IIIb randomized, double‐blind, parallel‐group, GUIDE study
Schäkel, K., Reich, K., Asadullah, K., Pinter, A., Jullien, D., Weisenseel, P., Paul, C., Gomez, M., Wegner, S., Personke, Y., Kreimendahl, F., Chen, Y., Angsana, J., Leung, M. W. L., Eyerich, K.
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2023)
Published in Journal of the European Academy of Dermatology and Venereology (01.10.2023)
Get full text
Journal Article
Real‐world evidence from the non‐interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab
Gerdes, S., Asadullah, K., Hoffmann, M., Korge, B., Mortazawi, D., Wegner, S., Personke, Y., Gomez, M., Sticherling, M.
Published in Journal of the European Academy of Dermatology and Venereology (01.09.2022)
Published in Journal of the European Academy of Dermatology and Venereology (01.09.2022)
Get full text
Journal Article
Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST study
Gerdes, S, Hoffmann, M, Asadullah, K, Korge, B, Mortazawi, D, Krüger, N, Personke, Y, Tabori, S, Gomez, M, Wegner, S, Kreimendahl, F, Taut, F, Sticherling, M
Published in Journal of the European Academy of Dermatology and Venereology (18.07.2023)
Published in Journal of the European Academy of Dermatology and Venereology (18.07.2023)
Get full text
Journal Article
Online weight-loss coaching for patients with psoriasis: results of a pilot study
Gerdes, S., Dethlefs, B., Personke, Y., Storim, J., Mrowietz, U.
Published in British journal of dermatology (1951) (01.03.2016)
Published in British journal of dermatology (1951) (01.03.2016)
Get full text
Journal Article
083 Prolonged Q16W treatment interval of guselkumab is non-inferior to Q8W dosing for maintaining disease control in super responders: primary results from GUIDE at Week 68 in patients with psoriasis
Schäkel, K., Asadullah, K., Pinter, A., Paul, C., Weisenseel, P., Gomez, M., Wegner, S., Personke, Y., Krüger, N., Eyerich, K.
Published in Journal of investigative dermatology (01.12.2022)
Published in Journal of investigative dermatology (01.12.2022)
Get full text
Journal Article
587 Higher IL-10+ T cell and treg cell counts in psoriatic skin are associated with super-response to guselkumab: Data from the phase 3 guide trial
Angsana, J., Kohler, K., Sendecki, J., Leung, M.W., Tabori, S., Krüger, N., Wegner, S., Personke, Y., Sabat, R., Wolk, K., Pinter, A., Weisenseel, P., Asadullah, K., Schäkel, K., Eyerich, K.
Published in Journal of investigative dermatology (01.05.2023)
Published in Journal of investigative dermatology (01.05.2023)
Get full text
Journal Article
Prognostic factors for early PASI 100 response in psoriasis patients treated with guselkumab: Results from the GUIDE study
Schakel, K, Reich, K, Asadullah, K, Pinter, A, Jullien, D, Weisenseel, P, Paul, C, Gomez, M, Wegner, S, Personke, Y, Eyerich, K
Published in JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Get full text
Published in JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Conference Proceeding
Early disease intervention in psoriasis leads to a faster and higher rate of complete skin clearance: Week 28 results from the GUIDE study
Schakel, K, Reich, K, Asadullah, K, Pinter, A, Jullien, D, Weisenseel, P, Paul, C, Gomez-Camacho, M, Wegner, S, Personke, Y, Chen, Y, Chen, K, Pinho, FO, Leung, M, Eyerich, K
Published in EXPERIMENTAL DERMATOLOGY (2021)
Get full text
Published in EXPERIMENTAL DERMATOLOGY (2021)
Conference Proceeding